Bone loss and glucocorticoid therapy in patients with respiratory disease

Thorax

Volumn 54, Issue SUPPL. 2, 1999, Pages

  Fairney, Angela ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; PREDNISOLONE; VITAMIN D;

ASTHMA; BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE REMODELING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; ESTROGEN THERAPY; FRACTURE; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; STEROID THERAPY;

EID: 0032772499     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.2008.s52     Document Type: Review

References (65)

1. 1 Gennari C. Glucocorticoid induced osteoporosis. Clin Endocrinol 1994; 41:273-4.
2. 2 Adinoff AD, Hollister JR. Steroid induced fractures and bone loss in asthma. N Engl J Med 1983;309:265-8.
3. 3 Spector TD, Hall GM, McCloskey EV, et al. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993;306:558.
4. 4 Reid DM, Nicoll JJ, Smith MA, et al. Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica. BMJ 1986;293:1463-6.
5. 5 Pearce G, Ryan PFJ, Delmas PD, et al. The deleterious effects of low dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol 1998;37:292-9.
6. 6 Sambrook P, Birmingham J, Kempler S, et al. Corticosteroid effects on proximal femur bone loss. J Bone Mineral Res 1990;5:1211-6.
7. 7 Royal College of Physicians, Osteoporosis, clinical guidelines for prevention and treatment. London: Royal College of Physician, 1999.
8. 8 Department of Health. Quick reference primary care guide on the prevention and treatment of osteoporosis. London: Department of Health, 1998.
9. 9 Lukert BP, Kream BE. Clinical and basic aspects of glucocorticoid action in bone. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of bone biology. London: Academic Press, 1996: 533-48.
10. 10 Eastell R, Reid DM, Compston J, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998;244:271-92.
11. 11 National Osteoporosis Society. Guidance on the prevention and management of corticosteroid induced osteoporosis. Bath, UK: National Osteoporosis Society, 1998.
12. 12 Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established conicosteroid induced osteoporosis. Am J Med 1995;99:235-42.
13. 13 Saag KG, Enikey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid induced osteoporosis. N Engl J Med 1998;339:292-9.
14. 14 Compston JE, Andran M, Avouac B, et al. Recommendations for the registration of agents in the prevention and treatment of glucocorticoid induced osteoporosis. Calcif Tissue Int 1996;59:323-7.
15. 15 American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheum 1996;39:1791-801.
16. 16 Scientific Advisory Board, Osteoporosis Society of Canada. Clinical practice guidelines for the diagnosis and management of osteoporosis. Can Med Assoc J 1996;155:1113-33.
17. 17 Lukert B. Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. London: Academic Press, 1996: 801-20.
18. 18 Cowan S, Morin S, Ernst P. Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases. Thorax 1998;53:331-2.
19. 19 Tobias JH. Management of steroid-induced osteoporosis: what is the current state of play? Rheumatology 1999;38:198-201.
20. 20 Reid DM. Corticoid induced osteoporosis: guidelines for prevention -are they useful? Br J Rheumatol 1997;36:1035-6.
21. 21 Stevenson JC. Management of corticosteroid-induced osteoporosis. Lancet 1998;352:1327-8.
22. 22 Seeman E, Ryan PJ. Bone turnover and bone mass in polymyalgia rheumatica. Rheumatology 1999;38:386.
23. 23 Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis Int 1998;8(Suppl 4).
24. 24 World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. Geneva: WHO, 1994.
25. 25 Kanis JA, Melton JL, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Mineral Res 1994;9:1137-41.
26. 26 Blake GM, Wahner HW, Fogelman I. The evaluation of osteoporosis: dual energy x-ray absorptiometry and ultrasound in clinical practice. 2nd ed. UK: Martin Dunitz, 1999.
27. 27 Canalis E. Regulation of bone remodelling. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 3rd ed. Philadelphia: Lippincott-Raven, 1996: 29-34.
28. 28 Munday GR. Bone remodelling and its disorders. UK: Martin Dunitz, 1995.
29. 29 Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocrine Rev 1996;17:333-68.
30. 30 Thompson JM, Modin GW, Arnaud CD, et al. Not all postmenopausal women on chronic steroid and oestrogen treatment are osteoporotic: predictors of bone mineral density. Calcif Tissue Int 1997;61:377-81.
31. 31 Dolan AL, Moniz C, Dasgupta B, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997;40:2022-9.
32. 32 Dasgupta B, Panayi GS. Interleukin 6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990;29: 456.
33. 33 Boyce BF, Hughes DE, Wright KR, et al. Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Lab Invest 1999;79:83-94.
34. 34 Walsh LJ, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6.
35. 35 Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 1995;332: 868-75.
36. 36 Puolijoki H, Liippo K, Herrala J, et al. Inhaled beclomethasone decreases serum ostcocalcin in postmenopausal asthmatic women. Bone 1992; 13:285-8.
37. 37 Packe GE, Douglas JG, McDonald AF, et at. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax 1992;47:414-7.
38. 38 Kerstjens HAM, Postma DS, van Doormaal JJ, et al. Effects of short term and long term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Thorax 1994;49: 652-6.
39. 39 Herrala J, Puolijki H, Impivaara O, et al. Bone mineral density in asthmatic women on high dose inhaled beclomethasone dipropionate. Bone 1994;15:621-3.
40. 40 Toogood JH, Barkerville JC, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995;96:157-66.
41. 41 Hughes JA, Conry BG, Male SM, et al. One year prospective open study of the effect of high dose inhaled steroids fluticasone propionate and budesonide on bone markers and bone mineral density. Thorax 1999;54:223-9.
42. 42 Dempster DW. Bone histomorphometry in glucocorticoid induced osteoporosis. J Bone Mineral Res 1989;4:137-41.
43. 43 Reid IR, Chapman GE, Fraser TRC, et al. Low serum osteocalcin levels in glucocorticoid treated asthmatics. J Clin Endocrinol Metab 1986; 62:379-83.
44. 44 Meunier PJ, Dempster DW, Edouard D, et al. Bone histomorphometry in corticosteroid induced osteoporosis and Cushings syndrome. Adv Exp Med Biol 1984;171:191-200.
45. 45 Pocock NA, Eisman JA, Dunstan CR, et al. Recovery from steroid-induced osteoporosis. Ann Intern Med 1987;107:319-23.
46. 46 Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient. 3rd ed. Parthenon Publishing, 1997.
47. 47 Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998;338:485-92.
48. 48 Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
49. 49 Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-47.
50. 50 Kyd PA, DeVooght K, Kerkhoff F, et al. Clinical usefulness of bone alkaline phosphatase in osteoporosis. Ann Clin Biochem 1998;35: 717-25.
51. 51 Kyd PA, DeVooght K, Kerkhoff F, Et al. Clinical usefulness of biochemical resorption markers in osteoporosis. Ann Clin Biochem 1999; 36 (in press).
52. 52 Gamero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79:1693-700.
53. 53 Stein GS, Lian JB. Molecular mechanisms mediating proliferation/ differentiation interrelationships during progressive development of the osteoblast phenotype. Endocrine Rev 1993;14:424-42.
54. 54 Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 1997; 337:383-7.
55. 55 Pitt P, Li F, Todd P, et al. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 1998;53:351-6.
56. 56 Roux C, Oriente P, Laan R, et al. Randomised trial of effect of cyclical etidronate in the prevention of corticosteroid induced bone loss. J Clin Endocrinol Metab 1998;83:1128-33.
57. 57 Gonnelli S, Rottoli P, Cepollaro C, et al. Prevention of corticosteroid induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 1997;61:382-5.
58. 58 Heaney RP. The bone remodelling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Mineral Res 1994;9:1515-23.
59. 59 Wats NB, Harsi ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323: 71-9.
60. 60 Geddes AD, DSouza SM, Ebetin FH, et al. Bisphosphonates: structure-activity relationships and therapeutic implications. In: Heersche JNM, Kanis JA, eds. Bone and mineral. Volume 8. Oxford: Elsevier Science, 1994: 265-306.
61. 61 Caggiano TJ, Zask A, Bex F. Recent advances in bone metabolism and osteoporosis research. In: Annual reports in medicinal chemistry. Volume 26. New York: Academic Press, 1991: 201-10.
62. 62 Frith JC, Monkkonen J, Blackburn GM, et al. Clodronate and liposome-encapsulated clodronate are metabolised to a toxic APT analog, adenosine (5-(β-dichloromethylene) triphosphate by mammalian cells in vitro. J Bone Mineral Res 1997;12:1358-67.
63. 63 Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen containing bisphosphonates inhibit the mevalonate pathway and prevent post translational prenylation of GTP binding proteins, including Ras. J Bone Mineral Res 1998;13:581-9.
64. 64 Monkkonen J, Simila J, Rogers MJ. Effects of tiludronate and ibandronate on proinflammatory cytokine and nitric oxide secretion from macrophages. Bone 1998;22(Suppl B19).
65. 65 Luengo M, Picado C, Rio LD, et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study. Thorax 1991;46:803-6.